血清 CXCR-2 评估在结直肠癌（CRC）患者中的临床实用性。

The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients.

机构信息

Department of Biochemical Diagnostics, Medical University in Bialystok, Bialystok, Poland;

Department of Biochemical Diagnostics, Medical University in Bialystok, Bialystok, Poland.

出版信息

Anticancer Res. 2021 Mar;41(3):1421-1428. doi: 10.21873/anticanres.14899.

DOI:10.21873/anticanres.14899

PMID:33788733

Abstract

BACKGROUND/AIM: The current study aimed to evaluate the clinical utility of the levels of the C-X-C-motif chemokine receptor-2 (CXCR-2) serum receptor in comparison to the carcinoembryonic antigen (CEA) tumor marker and - the C-reactive protein (CRP) inflammatory marker in the diagnosis and prognosis of colorectal cancer (CRC).

MATERIALS AND METHODS

Our study comprised 59 patients with CRC and 46 healthy subjects. Serum concentrations of the analyzed proteins were measured using enzyme-linked immunosorbent assay, chemiluminescent microparticle immunoassay and immunoturbidimetric methods.

RESULTS

Serum levels of CXCR-2 were lower, while those of CEA and CRP were significantly higher in CRC patients in comparison to the control group. The diagnostic sensitivity of CXCR-2 was higher than that of CEA, and increased when CXCR-2 analysis was combined with CEA or CRP.

CONCLUSION

According to our knowledge, this is the first study concerning the significance of CXCR2 as a CRC biomarker. Measurement of the serum levels of CXCR-2 may improve the diagnosis efficiency of CRC patients, especially in combination with the tumor marker CEA.

摘要

背景/目的：本研究旨在评估 C-X-C 基序趋化因子受体 2（CXCR-2）血清受体水平与癌胚抗原（CEA）肿瘤标志物和 C-反应蛋白（CRP）炎症标志物相比，在结直肠癌（CRC）诊断和预后中的临床应用价值。